1-10 of 10
Jutta Deckert
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients with Advanced B-Cell Non-Hodgkin Lymphomas (NHL)

Sarit Assouline, Katharine L. Lewis, Rosemary Anne Harrup, Robert J Lutz, Jenny Thirlway, Jutta Deckert, David M Browning, Debra L Wood, Paul I. Nadler, Seung Tae Lee
Journal: Blood
Blood (2023) 142 (Supplement 1): 3095.
https://doi.org/10.1182/blood-2023-173955
Published: 2023
Journal Articles

IKS03, a Novel CD19-Targeted Antibody Drug Conjugate, Induces Target Dependent In Vivo Cell Killing of B-Cell Lymphoma Xenografts By DNA Crosslinking

Jutta Deckert, Jenny Thirlway, Justyna Mysliwy, Adam Lodge, Robert J Lutz
Journal: Blood
Blood (2023) 142 (Supplement 1): 1438.
https://doi.org/10.1182/blood-2023-174064
Published: 2023
Journal Articles

IKS03, a Next Generation CD19-Targeted Antibody Drug Conjugate, Shows Potent Activity in Preclinical Models of Aggressive B-Cell Lymphomas

Jutta Deckert, Jenny Thirlway, Justyna Mysliwy, Adam Lodge, Yun-Hee Park, Hyun-Min Ryu, Na Ra Han, Ho Young Song, Chul-Woong Chung, Robert J Lutz
Journal: Blood
Blood (2022) 140 (Supplement 1): 3134–3135.
https://doi.org/10.1182/blood-2022-158983
Published: 2022
Journal Articles

Coltuximab Ravtansine (SAR3419) Demonstrates Enhanced Activity in Combination with Bendamustine, Gemcitabine and Novel Targeted Agents Such As PI3K Inhibitors in Pre-Clinical Models of Relapsed and/or Refractory Non-Hodgkins Lymphoma (NHL)

Callum M Sloss, PhD, Katie O'Callaghan, PhD, Jutta Deckert, PhD, Jenny Tsui, BS, Leanne Lanieri, BS, Angela Romanelli, PhD
Journal: Blood
Blood (2015) 126 (23): 5125.
https://doi.org/10.1182/blood.V126.23.5125.5125
Published: 2015
Journal Articles

IMGN529, a Novel Antibody-Drug Conjugate (ADC) Targeting CD37 Shows Synergistic Activity with Rituximab in Non-Hodgkin Lymphoma (NHL) Models

Jutta Deckert, PhD, Callum M Sloss, PhD, Katie O'Callaghan, PhD, Jenny Tsui, BS, Nemisha Dawra, BS, Yong Yi, MD, Jennifer A Coccia, BS, Leanne Lanieri, BS, Sharon Chicklas, BS, Angela Romanelli, PhD
Journal: Blood
Blood (2015) 126 (23): 1548.
https://doi.org/10.1182/blood.V126.23.1548.1548
Published: 2015
Journal Articles

Preclinical Mechanistic Studies Investigating Neutrophil and Lymphoid Cell Depletion By IMGN529, a CD37-Targeting Antibody-Drug Conjugate (ADC)

Jutta Deckert, PhD, Jose F. Ponte, PhD, Jennifer A. Coccia, Leanne Lanieri, Sharon Chicklas, Yong Yi, Krystal Watkins, Rodrigo Ruiz-Soto, MD MSc, Angela Romanelli, PhD, Robert J. Lutz, PhD
Journal: Blood
Blood (2014) 124 (21): 3119.
https://doi.org/10.1182/blood.V124.21.3119.3119
Published: 2014
Journal Articles

A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies

Jutta Deckert, Peter U. Park, Sharon Chicklas, Yong Yi, Min Li, Katharine C. Lai, Michele F. Mayo, Christina N. Carrigan, Hans K. Erickson, Jan Pinkas, Robert J. Lutz, Thomas Chittenden, John M. Lambert
Journal: Blood
Blood (2013) 122 (20): 3500–3510.
https://doi.org/10.1182/blood-2013-05-505685
Published: 2013
Journal Articles

A Transgenic Mouse Model of Aggressive B-Cell Malignancy for Evaluating Anti-Human CD37 Therapeutics

Kyle A Beckwith, B.S., Frank W Frissora, M.S., Matthew R Stefanovski, B.S., Jutta Deckert, Ph.D., Carlo M Croce, M.D., Xiaokui Mo, PhD, David Jarjoura, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D
Journal: Blood
Blood (2012) 120 (21): 188.
https://doi.org/10.1182/blood.V120.21.188.188
Published: 2012
Journal Articles

Potent B-Cell Depletion by IMGN529, a CD37-Targeting Antibody-Maytansinoid Conjugate for the Treatment of B-Cell Malignancies,

Jutta Deckert, Ph.D., Sharon Chicklas, Yong Yi, Min Li, Jan Pinkas, Ph. D., Thomas Chittenden, Ph.D., Robert J. Lutz, PhD, Peter U. Park, Ph.D.
Journal: Blood
Blood (2011) 118 (21): 3726.
https://doi.org/10.1182/blood.V118.21.3726.3726
Published: 2011
Journal Articles

SAR650984: A Potent Anti-CD38 Therapeutic Antibody with Three Mechanisms of Action (Apoptosis, ADCC, CDC) for Hematological Malignancies

Peter U. Park, Véronique Blanc, Jutta Deckert, Pascale Lejeune, Laura M. Bartle, Anna Skaletskaya, Michele F. Mayo, Chonghui Zhang, Marie-Cécile Wetzel, Daniel J. Tavares, Robert J. Lutz, Thomas Chittenden, Marie-Christine Bissery, John M. Lambert, Victor S. Goldmacher
Journal: Blood
Blood (2008) 112 (11): 2756.
https://doi.org/10.1182/blood.V112.11.2756.2756
Published: 2008